Category: Healthcare

57A Epirus Road
Fulham Broadway
London, SW6 7UR
United Kingdom


Almost 400 million people worldwide suffer from diabetes and obesity.  Until now, this problem has been managed with invasive and risky techniques (so-called ‘metabolic surgery’), but new perspectives are now opening up thanks to the technology developed by Keyron.

The biomedical startup aims at offering an alternative to bariatric surgery, a highly invasive technique often rejected by patients due to the high risk of complications and collateral damage, including death. Keyron’s innovation – fully patented – achieves the benefits of surgery, without the associated risks. In fact, a medical device, inserted by endoscopy, induces the same effects as gastric bypass on diabetes and obesity, but without surgery.

Keyron is offering the “Sleevebaloon”, a device with an innovative design that enables non-invasive bypass at duodenal level, overcoming the small intestine and managing to normalise diabetes and significantly reduce obesity thanks to its enormous metabolic benefits.

The discovery was published in a Lancet Group journal, EBioMedicine, with an impact factor of more than 5. The preclinical study showed that the Sleevebaloon induces a complete normalisation of diabetes and weight reduction equivalent to the effects of bariatric surgery.


LIFTT Investment

In portfolio: Q3 2021
Venture phase: Start-up
LIFTT funding: ~ 1M€
Round: 2

LIFTT Project Manager
Go to Top